Novartis AG Sponsored ADR (NVS.US) has received approval for Phase 1 clinical trial of a new drug for radioactive cancer therapy in China.

On March 3rd, the China National Medical Products Administration Drug Evaluation Center (CDE) official website announced that the 1st class new drug [225Ac]Ac-PSMA-617 injection sponsored by Novartis AG Sponsored ADR (NVS.US) has been approved for clinical trials. It is intended to be developed for the treatment of PSMA-positive metastatic castration-resistant prostate cancer that has progressed during or after [177Lu]Lu-PSMA targeted therapy. According to Novartis AG Sponsored ADR pipeline data on their official website, this is a targeted PSMA radioligand therapy (research and development code: AAA817) that has entered the 2/3 phase clinical trials internationally. This is the first time this product has been approved for an investigational new drug (IND) in China. Radioactive drugs have attracted much attention in recent years due to their unique "diagnostic and therapeutic integration" feature. They use the same tumor markers as targets, using radio-labeled imaging (RLI) technology to search and locate tumor lesions, and then implement precise attacks on cancer cells using radio-labeled therapy (RLT) drugs targeting the same target, offering advantages of precision, efficiency, and minimal side effects.